The document discusses the trend of consolidation in the healthcare sector, particularly in pathology organizations. Economic pressures have led to decreased budgets, forcing providers to do more with less. This has resulted in incentives to consolidate operations in order to improve efficiency and cope with these constraints. Consolidation allows organizations to improve productivity, achieve cost savings, and allocate resources more effectively. However, achieving additional savings through consolidation is becoming more difficult due to previous rounds of consolidation. Certainty around the impact of changes is critical, especially with increased risk, and tools like PinpointBPSTM can provide the required accuracy and detail to support consolidation decisions.
Integrate RWE into clinical developmentIMSHealthRWES
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the author’s experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.
Technology is disrupting the process behind drug development. Growing realization that current clinical trial strategies are not sustainable or feasible means one thing - change. But, where do pharmaceutical companies go from here? An integrated clinical trial ecosystem will arise through leveraging emerging business technologies. But, are companies prepared to take advantage?
David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
Integrate RWE into clinical developmentIMSHealthRWES
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the author’s experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.
Technology is disrupting the process behind drug development. Growing realization that current clinical trial strategies are not sustainable or feasible means one thing - change. But, where do pharmaceutical companies go from here? An integrated clinical trial ecosystem will arise through leveraging emerging business technologies. But, are companies prepared to take advantage?
David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...Covance
Premarketing clinical safety and PV activities, and the technology infrastructure that supports it, are typically outsourced to multiple contract research organisations (CROs) as part of their clinical trial programmes. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Many leading pharmaceutical companies recognize the need to explore different means and mechanisms to supply physicians and their patients with samples of prescription medications. This is especially true since many physicians have restricted access to the sales reps that traditionally helped order and restock samples as part of their detailing visits.
While some companies have made substantial forays into the world of physician e-sampling, usually as a supplement to traditional sampling, others have done less in this area. This is important when you consider that 30 percent of patients in the United States are more likely to fill a prescription after initially receiving a sample from a physician. This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
Capturing the Value Proposition: Repositioning hospital service linesJames Case
Service line planning in a value-based care environment has taken on new dimensions. We outline an approach to planning and operations that will allow providers to differentiate in the market, drive volume, and improve the patient experience of care.
Nursing Peer Review to Improve Quality and Reduce Costs 2014iCareQuality.us
A system engineering approach is used to reduce frontline nursing care variability by integrating peer review to enhance quality of care efforts on the frontline.
We are driven by a passionfor transforming products into brands and patients into survivors. Navicor is a 100% healthcare-focused, full-service agency that understands the unique aspects of the oncology marketplace. We have extensive oncology launch experience and have partnerships with large and small pharma and biotech companies.
Healthcare logistics for service improvement and a new understanding of patient flow. Presented by Delia Dent, CSC, at HINZ 2014, 11 November 2014, 11.37am, Marlborough Room
Sharing a New Ideal: How Tomorrow’s Understaffed, Multi-Site Lab Organization...mhartman1309
This presentation was presented by Chris Christopher at the Lab Quality Confab Conference on Nov 2, 2010. It shows how medical laboratories are using automation, technology and lean sigma improvement methodologies to meet organizational needs.
Safety & Regulatory Solutions for Small and Medium-sized Life Science Organiz...Covance
A key issue for small and medium-sized enterprises is the optimal utilization of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved product(s). This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement and globalization. Yet companies face overwhelming pressure to get their product to market as quickly as possible.
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...Covance
Premarketing clinical safety and PV activities, and the technology infrastructure that supports it, are typically outsourced to multiple contract research organisations (CROs) as part of their clinical trial programmes. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Many leading pharmaceutical companies recognize the need to explore different means and mechanisms to supply physicians and their patients with samples of prescription medications. This is especially true since many physicians have restricted access to the sales reps that traditionally helped order and restock samples as part of their detailing visits.
While some companies have made substantial forays into the world of physician e-sampling, usually as a supplement to traditional sampling, others have done less in this area. This is important when you consider that 30 percent of patients in the United States are more likely to fill a prescription after initially receiving a sample from a physician. This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
Capturing the Value Proposition: Repositioning hospital service linesJames Case
Service line planning in a value-based care environment has taken on new dimensions. We outline an approach to planning and operations that will allow providers to differentiate in the market, drive volume, and improve the patient experience of care.
Nursing Peer Review to Improve Quality and Reduce Costs 2014iCareQuality.us
A system engineering approach is used to reduce frontline nursing care variability by integrating peer review to enhance quality of care efforts on the frontline.
We are driven by a passionfor transforming products into brands and patients into survivors. Navicor is a 100% healthcare-focused, full-service agency that understands the unique aspects of the oncology marketplace. We have extensive oncology launch experience and have partnerships with large and small pharma and biotech companies.
Healthcare logistics for service improvement and a new understanding of patient flow. Presented by Delia Dent, CSC, at HINZ 2014, 11 November 2014, 11.37am, Marlborough Room
Sharing a New Ideal: How Tomorrow’s Understaffed, Multi-Site Lab Organization...mhartman1309
This presentation was presented by Chris Christopher at the Lab Quality Confab Conference on Nov 2, 2010. It shows how medical laboratories are using automation, technology and lean sigma improvement methodologies to meet organizational needs.
Safety & Regulatory Solutions for Small and Medium-sized Life Science Organiz...Covance
A key issue for small and medium-sized enterprises is the optimal utilization of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved product(s). This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement and globalization. Yet companies face overwhelming pressure to get their product to market as quickly as possible.
Change Management And Contingency Planning in Transformation of Diagnostic De...Ruby Med Plus
Change Management and Contingency Planning: Case Study of Dental Hospital in implementing new Dental X-ray technology.Application of Kurt Lewin Force field Model. Kurt Lewin's three-stage model (1958) of organizational change,
State of the Musculoskeletal Service Line: What's New in 2013 and Beyond?Wellbe
Long a bastion of growth and profitability, the orthopedic service line has historically served as a reliable source of surgical volumes and attractive per case economics for hospitals and health systems.
However, the rate of profitable volume growth is progressively challenged by several recent trends, including soaring implant costs, wavering reimbursement, and intensifying competition, which includes the migration of care to ambulatory centers.
In addition, in the wake of the Patient Protection and Affordable Care Act (PPACA) of 2010, hospitals will increasingly be held accountable for delivering high-quality, low-cost orthopedic care. In this rapidly changing environment, the orthopedic service line will require careful management to ensure its continued success.
This presentation explores the most important business and structural challenges to musculoskeletal healthcare delivery, covering topics such as the impact of healthcare reform; physician alignment tactics; and strategies for organization, staffing, and structure.
Speaker Biographies:
Ms. Krista L. Fakoory, Manager
Ms. Fakoory has been providing healthcare management consulting services since 2006. Her background includes strategic and service line business planning, hospital/physician alignment, provider compensation planning, and merger and acquisition assistance. She has particular expertise in developing comprehensive orthopedic programs, strategic planning for physician-owned ambulatory surgery centers, and designing alignment models between health systems and independent orthopedic surgeons.
Mr. Todd W. Godfrey, Senior Manager
With nearly 15 years of healthcare experience, Mr. Godfrey has a focused background in musculoskeletal services. He regularly advises clients on performance-based incentives between surgeon and health systems as organizations position their musculoskeletal service line to assume risk and manage populations.
Five cost saving tactics for healthcare providers that lead to better outcomes on the income statement and individually can help providers with their bottom line, including reducing, reusing, refurbishing, reprocessing and reimbursement. For the full article, visit http://www.mdbuyline.com/blog/power-re/.
Boston Consulting Group partners with leaders
in business and society to tackle their most
important challenges and capture their greatest
opportunities. BCG was the pioneer in business
strategy when it was founded in 1963. Today,
we work closely with clients to embrace a
transformational approach aimed at benefiting all
stakeholders—empowering organizations to grow,
build sustainable competitive advantage, and
drive positive societal impact.
Our diverse, global teams bring deep industry and
functional expertise and a range of perspectives
that question the status quo and spark change.
BCG delivers solutions through leading-edge
management consulting, technology and design,
and corporate and digital ventures. We work in a
uniquely collaborative model across the firm and
throughout all levels of the client organization,
fueled by the goal of helping our clients thrive and
enabling them to make the world a better place.
Patient Driven Groupings Model (PDGM) represents a major
shift in wound management.
HHA (Home Health Agency) Owners/Operators can benefit from the high case-mix weightings within the new Clinical Groupings
1. DRIVE TOWARDS CONSOLIDATION
Economic pressures have resulted in government budgets
becoming more constrained and debt levels rising.
This has affected the public healthcare sector in particular.
Due to decreased budgets for pathology organisations, we
are seeing a trend of consolidation incentives in order to
cope with change.
Finding ways to operate more efficiently and deal with
reimbursement policies has led to the consolidation
trend, where providers are required to do more with less
and cope with the economies of scale. (2014, Healthcare
consolidation on the rise; Dvorak, Katie.)
BENEFITS OF CONSOLIDATION
The consolidation of services enables the organisation
to improve productivity, efficiency and quality, while
achieving savings on their annual budget. In the pathology
industry, the difference in the cost per test between
organisations is caused by two main factors: 1) the scope
of operations; and 2) the deployment of staff.
Bigger organisations can allocate their fixed cost across a
larger number of tests performed. There is also stronger
purchasing power for a bigger company in terms of
equipment and reagents. This means the difference in
equipment cost per test would be twice as much for a
laboratory processing 4-million tests per annum compared
to one processing 30-million tests, for example.
Equipment utilisation can fluctuate between 20% and
80% and this can be improved significantly through
consolidating more tests on to fewer analytical platforms.
The management of demand and capacity becomes more
effective through allocating resources against sample
arrival peaks, as well as absorbing more samples at times
when traditionally no work is being processed.
A further benefit of consolidation is an increase in the
productivity of current staff in the laboratory, as well as
more effective allocation of the required FTEs and the
use of their skill-mix. (DoH, Consolidation of Pathology
Services, 2009.)
UNDERSTANDING THE CURRENT
ENVIRONMENT
In our experience, having completed multiple
consolidation projects across the world, we have
realised that most organisations have either analysed or
implemented the merger of specialist departments around
technology where possible. This has made it troublesome
to extract additional savings through consolidation, which
is why we are likely to see movement toward a future
where technology alone does not drive consolidation.
Understanding consolidation in the current environment,
especially within the public sector, becomes more difficult
as savings start to lessen and become harder to achieve.
The next savings are not as obvious as before and there is
a greater risk to the organisation in achieving the benefits
of consolidation. This is where accuracy and certainty are
critical factors.
There have been successes and failures through a
standard route of trial and error in consolidation
within pathology organisations. However, when the
risks become greater than the perceived reward of a
successful consolidation project, there are two options
for an organisation to follow: 1) do not proceed due to
high risk and cost of failure; or 2) be absolutely certain
about the impact of change through consolidation prior to
implementation, in order to realise quantified savings.
How can a pathology director be absolutely certain
that the consolidation incentives will be realised in
their laboratory?
CONFIDENCE IS ESSENTIAL
When a consolidation initiative is taken on board by an
organisation, it is important to understand the exact
impact of volume changes with regards to resource
capacity and predictable turn-around time (pTAT).
There are multiple variables in the pathology laboratory,
rendering accuracy in decision making critical. Our clients
also cite the importance of knowing not only where
resources become available, but also the increased impact
on existing resources performing current tasks in
specific departments.
HOW PINPOINTBPS™ CAN HELP
PinpointBPS™ is a service that identifies real improvement
and cost-saving opportunities in complex environments,
such as diagnostic laboratories. PinpointBPS™ is based on
Lean and Six Sigma principles and it has been specifically
developed to provide pathology directors with the
required level of accuracy and detail to support
every decision.
Through PinpointBPS™, we have the capability to analyse
the technical feasibility of consolidation in depth within
an organisation. This has enabled identification of exact
departments where the minimum required resources are
needed due to workload changes and where resources
can be reallocated to achieve maximum savings.
The certainty provided by PinpointBPS™ enables decision
makers to follow through with implementation while
understanding the holistic impact of change initiatives
on their laboratory.
LTS has extensive experience in
understanding the operations of the
diagnostic industry, as well as long term
specialist modelling and decision support
knowledge. This enables LTS to offer your
organisation PinpopintBPS™ as a viable
continuous improvement asset resulting
in trust, accuracy and certainty to support
your decisions - from feasibility through
to implementation.
OUR
POINT
OF VIEW
20
15
ISSUE
04
www.LTSconsulting.com
POWERED BY
CONFORMITY IN
CONSOLIDATION
BY ANTTI LEINO, SENIOR INDUSTRIAL ENGINEER
How are the public pathology laboratories
dealing with decreased operational budgets
and sustaining increased test volumes, while
managing to keep their service up to the
required quality?